I

InflaRx NV
D

IFRX

0.81690
USD
0.02
(2.11%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
55,342,630
أصول ذات صلة
A
AMRN
0.025
(0.15%)
16.665 USD
C
CRBP
-0.15750
(-2.03%)
7.60000 USD
M
MTNB
-0.01000
(-1.06%)
0.93000 USD
V
VKTX
0.430
(1.55%)
28.150 USD
المزيد
الأخبار المقالات

العنوان: InflaRx NV

القطاع: Healthcare
الصناعة: Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.